Onconetix, Inc. (NASDAQ:ONCO) Short Interest Update

Onconetix, Inc. (NASDAQ:ONCO) was the recipient of a large decrease in short interest in the month of September. As of September 15th, there was short interest totalling 5,900 shares, a decrease of 99.2% from the August 31st total of 695,100 shares. Based on an average daily volume of 245,300 shares, the short-interest ratio is presently 0.0 days. Currently, 0.9% of the company’s stock are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Onconetix stock. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Onconetix, Inc. (NASDAQ:ONCO) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 306,079 shares of the company’s stock, valued at approximately $51,000. Zurcher Kantonalbank Zurich Cantonalbank owned approximately 1.37% of Onconetix as of its most recent SEC filing. 23.89% of the stock is owned by hedge funds and other institutional investors.

Onconetix Price Performance

ONCO stock opened at $3.36 on Friday. The company has a quick ratio of 0.09, a current ratio of 0.10 and a debt-to-equity ratio of 0.08. Onconetix has a fifty-two week low of $2.82 and a fifty-two week high of $23.05. The business has a 50-day moving average of $0.28 and a 200-day moving average of $0.20.

Onconetix (NASDAQ:ONCO) last released its quarterly earnings results on Thursday, August 29th. The company reported ($0.23) earnings per share for the quarter. The business had revenue of $0.71 million during the quarter.

Onconetix Company Profile

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.